CytomX Q2 2026 earnings: Collaboration revenue decline widens loss

CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2026 revenue of $1.4 million, down about 92% from $18.7 million a year earlier, while diluted loss per share widened to $0.09 from a loss of $0.00 after rounding. The net loss increased to $20.7 million as collaboration revenue declined and spending on Varseta-M manufacturing and development rose. CytomX ended June with $330.3 million in cash, cash equivalents and investments, excluding a $37.0 million Regeneron payment received in July.

Core financial results

Revenue declined primarily because CytomX completed its performance obligation under the Bristol Myers Squibb collaborations during 2025. Lower research activity under the Astellas collaboration, which concluded during Q2 2026, also reduced revenue.

Costs moved in the opposite direction. Total operating expenses rose by $5.3 million, led by increased Varseta-M manufacturing activity, personnel costs, consulting expenses and rent.

All figures are GAAP results and have been rounded. The prior-year diluted loss per share rounded to $0.00.

Pipeline and collaboration developments

Varsetatug masetecan, or Varseta-M, remains CytomX’s lead clinical program. Enrollment in its Phase 1 monotherapy study in advanced colorectal cancer is complete, with 113 patients across dose escalation, expansion and optimization. The dose-optimization cohorts enrolled 40 patients across the 8.6 mg/kg and 10 mg/kg every-three-week doses.

CytomX expects a Phase 1 monotherapy update by the end of 2026, focused on selecting a dose for later-stage development. The company also plans discussions with the FDA as it works toward starting its first monotherapy registrational study in colorectal cancer during the first half of 2027.

Development is expanding beyond late-line monotherapy:

• A Phase 1 study combining Varseta-M with bevacizumab in third-line and later metastatic colorectal cancer is underway, with initial data anticipated in the first half of 2027.
• A Phase 1/2 study combining Varseta-M with bevacizumab, 5-fluorouracil and leucovorin in second-line metastatic colorectal cancer is scheduled to begin in Q4 2026.
• Monotherapy expansion cohorts in gastric and gastroesophageal junction cancer, EpCAM-selected pancreatic ductal adenocarcinoma and EpCAM-selected biliary tract cancer are initiating in Q3 2026.

For CX-801, the monotherapy portion of the Phase 1 melanoma study has reached its fourth dose level. The combination with Keytruda has cleared the third dose level, with initial combination data expected in the first half of 2027.

CytomX also expanded its Regeneron collaboration in June 2026. Regeneron selected two additional programs, triggering a $37.0 million payment received in July, and obtained options to select up to six more targets. The collaboration now covers up to approximately $4.0 billion in potential target-nomination, research, development, regulatory and sales-based milestones, although those milestone amounts are contingent rather than committed revenue.

Profitability, cash and balance-sheet capacity

Cash, cash equivalents and investments declined by $16.4 million from $346.7 million at March 31 to $330.3 million at June 30, a sequential decrease of about 5%. The June balance excludes the subsequent $37.0 million Regeneron payment.

The higher operating loss reflects both the loss of collaboration revenue and increased clinical investment. R&D expense rose by $4.3 million, mainly because of Varseta-M manufacturing, personnel and broader research costs. G&A expense increased by $1.0 million due principally to consulting and rent.

Interest income of $3.2 million partially offset the $23.8 million operating loss, resulting in a $20.7 million net loss. CytomX’s cash position remains the main financial buffer as its programs progress through early-stage clinical development.

Outlook and upcoming milestones

CytomX expects its existing resources to fund operations to at least the second half of 2028. The stated runway extends beyond the company’s principal clinical milestones currently scheduled through the first half of 2027.

Recent insider transactions

The supplied transaction-level data lists five sales and five stock awards among the latest 10 entries, all recorded as direct holdings. A separate six-month aggregate in the same dataset reports zero purchase and sale transactions, which conflicts with these dated records; the table therefore presents the detailed entries without drawing a conclusion about insider sentiment.

Risks investors need to monitor

• Early-stage clinical uncertainty: Varseta-M and CX-801 remain in Phase 1 development. Initial safety or efficacy results may not be predictive of later-stage trials or regulatory outcomes.
• Dependence on Varseta-M milestones: Dose selection, FDA alignment and the planned registrational study are central to CytomX’s development strategy. Delays or unfavorable data could materially alter the timeline.
• Volatile collaboration revenue: The sharp quarterly revenue decline followed the completion or conclusion of collaboration activities. Future revenue may remain uneven because it depends on partner work and milestone achievement.
• Rising development costs: Varseta-M manufacturing and personnel expenses increased R&D spending during the quarter. Higher-than-planned clinical or manufacturing costs could shorten the projected cash runway.
• Manufacturing reliance: CytomX depends on third parties to manufacture its product candidates, creating execution and cost risks as clinical programs expand.

Summary

CytomX’s Q2 2026 results reflected a transition from comparatively high collaboration revenue toward heavier internal clinical investment, producing a wider operating and net loss. The company’s $330.3 million quarter-end cash and investment balance, supplemented by the July Regeneron payment, supports a stated runway into at least the second half of 2028. The next major operating tests are the year-end Varseta-M data update, dose selection, FDA alignment and execution of multiple planned studies through 2027.